National Institute on Drug Abuse; Notice of Closed Meeting, 21006-21007 [2010-9301]

Download as PDF 21006 Federal Register / Vol. 75, No. 77 / Thursday, April 22, 2010 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2010–N–0001] Town Hall Discussion With the Director of the Center for Devices and Radiological Health and Other Senior Center Management AGENCY: Food and Drug Administration, HHS. srobinson on DSKHWCL6B1PROD with NOTICES ACTION: Notice of public meeting; request for comments. The Food and Drug Administration (FDA) is announcing a public meeting entitled: ‘‘Town Hall Discussion With the Director of the Center for Devices and Radiological Health and Other Senior Center Management.’’ The purpose of this meeting is to present the Center for Devices and Radiological Health (CDRH) fiscal year (FY) 2010 priorities. In addition, FDA is interested in engaging in discussions about issues that are of importance to the medical device industry. Dates and Time: The public meeting will be held on May 18, 2010, from 9 a.m. to 4 p.m. Location: The public meeting will be held at the Hilton Minneapolis, Saint Paul Airport, 3800 American Blvd. East, Bloomington, MN, 55425–1658. The meeting will not be videotaped or webcast. Contact Person: Heather Howell, Food and Drug Administration, Center for Devices and Radiological Health, 10903 New Hampshire Ave., Bldg. 66 (rm. 4320), Silver Spring, MD 20993, 301– 796–5718, e-mail: heather.howell@fda.hhs.gov. Registration and Requests for Oral Presentations: If you wish to attend the public meeting, you must register online at: https://www.fda.gov/MedicalDevices/ NewsEvents/WorkshopsConferences/ ucm206671.htm. Provide complete contact information for each attendee, including: Name, title, company or organization, address, e-mail, and telephone number. Registration requests must be received by 5 p.m. on Wednesday, May 5, 2010. If you wish to make an oral presentation during any of the sessions at the meeting (see section II of this document), you must indicate this at the time of registration. FDA will do its best to accommodate requests to speak. Individuals and organizations with common interests are urged to consolidate or coordinate their presentations, and to request time for a joint presentation. FDA will determine the amount of time allotted to each VerDate Nov<24>2008 18:52 Apr 21, 2010 Jkt 220001 presenter and the approximate time that each oral presentation is scheduled to begin. Registration is free and will be on a first-come, first-served basis. Early registration is recommended because seating is limited. FDA may limit the number of participants from each organization based on space limitations. Registrants will receive confirmation once they have been accepted. Onsite registration on the day of the public meeting will be provided on a spaceavailable basis beginning at 8 a.m. If you need special accommodations due to a disability, please contact Susan Monahan at 301–796–5661 or susan.monahan@fda.hhs.gov at least 7 days in advance of the meeting. Comments: FDA is holding this public meeting to share information and discuss issues of importance to the medical device industry. CDRH is specifically interested in addressing the following question: What mechanism(s) would you prefer or suggest for FDA to engage with industry? The deadline for responding to this question and for submitting other comments related to this public meeting is Wednesday, May 5, 2010. Regardless of attendance at the public meeting, interested persons may submit electronic or written comments. Submit electronic comments to https:// www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. SUPPLEMENTARY INFORMATION: in discussions about issues that are of importance to the medical device industry. CDRH wishes to obtain feedback/ideas for facilitating two-way communication between CDRH and the medical device industry. The meeting will open with an introduction of CDRH Senior Staff in attendance. Following introductions, Jeffrey Shuren, the Director of CDRH, will present the FY 2010 CDRH priorities. Industry representatives and other members of the public will then be given the opportunity to present comments to CDRH Senior Staff. Attendees from CDRH may respond to questions presented by industry and other members of the public. In advance of the meeting, additional information, including a meeting agenda with a speakers’ schedule, will be made available on the Internet. This information will be placed on file in the public docket (docket number found in brackets in the heading of this document), which is available at https:// www.regulations.gov. This information will also be available at https:// www.fda.gov/MedicalDevices/News Events/WorkshopsConferences/ default.htm (select the appropriate meeting from the list). I. Background CDRH has announced four priority areas of activity for fiscal year 2010, each of which presents significant opportunities to improve the Center’s effectiveness in fulfilling our public health mission. More information, including specific goals and actions associated with each priority, is available under ‘‘CDRH Strategic Planning’’ at: www.fda.gov/AboutFDA/ CentersOffices/CDRH. DEPARTMENT OF HEALTH AND HUMAN SERVICES II. Public Meeting The objective of this public meeting is to present CDRH FY 2010 priorities. In addition, FDA is interested in engaging PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 III. Transcripts Transcripts of the public meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, rm. 6–30, Rockville, MD 20857, approximately 15 working days after the public meeting at a cost of 10 cents per page. A transcript of the public meeting will be available on the Internet at https://www.regulations.gov. Dated: April 16, 2010. Leslie Kux, Acting Assistant Commissioner for Policy. [FR Doc. 2010–9242 Filed 4–21–10; 8:45 am] BILLING CODE 4160–01–S National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose E:\FR\FM\22APN1.SGM 22APN1 Federal Register / Vol. 75, No. 77 / Thursday, April 22, 2010 / Notices confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; R25 Review (PAR–07–221). Date: April 29, 2010. Time: 12 p.m. to 2 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852. (Telephone Conference Call) Contact Person: Jose F. Ruiz, Ph.D., Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, 6101 Executive Blvd., Rm. 213, MSC 8401, Bethesda, MD 20892, 301– 451–3086, ruizjf@nida.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: April 16, 2010. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Virtual Meeting) Contact Person: Roberto J. Matus, MD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5108, MSC 7854, Bethesda, MD 20892. (301) 435– 2204. matusr@csr.nih.gov. Name of Committee: Surgical Sciences, Biomedical Imaging and Bioengineering Integrated Review Group, Bioengineering, Technology and Surgical Sciences Study Section. Date: May 17–18, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Khalid Masood, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5120, MSC 7854, Bethesda, MD 20892. 301–435– 2392. masoodk@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) [FR Doc. 2010–9301 Filed 4–21–10; 8:45 am] Dated: April 16, 2010. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. BILLING CODE 4140–01–P [FR Doc. 2010–9314 Filed 4–21–10; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health srobinson on DSKHWCL6B1PROD with NOTICES Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel, Member Conflict: SAT and BTSS Study Sections. Date: May 14, 2010. Time: 2 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. VerDate Nov<24>2008 18:25 Apr 21, 2010 Jkt 220001 Food and Drug Administration [Docket No. FDA–2010–N–0001] Food Labeling; Public Workshop AGENCY: Food and Drug Administration, HHS. ACTION: Notice of public workshop. SUMMARY: The Food and Drug Administration (FDA), Office of Regulatory Affairs (ORA), Dallas District Office (DALDO), in collaboration with Oklahoma State University (OSU), Robert M. Kerr Food & Agricultural Products Center (FAPC), is announcing a public workshop entitled ‘‘Food Labeling Workshop.’’ This public workshop is intended to provide information about FDA food labeling regulations and other related subjects to the regulated industry, particularly small businesses and startups. Date and Time: The public workshop will be held on May 17 and 18, 2010, from 8 a.m. to 5 p.m. PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 21007 Location: The public workshop will be held at FAPC, OSU, 148 FAPC, Stillwater, OK 74078–6055. Contact: David Arvelo, Food and Drug Administration, 4040 North Central Expressway, suite 900, Dallas, TX 75204, 214–253–4952, FAX: 214–253– 4970, or email: david.arvelo@fda.hhs.gov. For information on accommodation options, contact conference coordinators Karen Smith or Andrea Graves at FAPC, OSU, 148 FAPC, Stillwater, OK 74078– 6055, 405–744–6071, FAX: 405–744– 6313, or email: karenl.smith@okstate.edu or andrea.graves@okstate.edu. Registration: You are encouraged to register by May 3, 2010. The workshop has a $400 registration fee to cover the cost of facilities, materials, lunch, and breaks. Seats are limited; please submit your registration as soon as possible. Workshop space will be filled in order of receipt of registration. Those accepted into the workshop will receive confirmation. Registration will close after the workshop is filled. Registration at the site is not guaranteed, but may be possible on a space available basis on the day of the public workshop beginning at 8 a.m. The cost of registration at the site is $400 payable to FAPC. If you need special accommodations due to a disability, please contact Karen Smith (see Contact) at least 7 days in advance. There are no registration fees for FDA employees. More information is also available online at https://www.fapc.biz/ foodlabeling.html. (FDA has verified the Web site address, but we are not responsible for any subsequent changes to the Web site after this document publishes in the Federal Register.) Registration form instructions: To register, please complete the online registration form at https://www.fapc.biz/ forms/foodlabeling.htm. Transcripts: Transcripts of the public workshop will not be available due to the format of this workshop. Course handouts may be requested at cost through the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A–16, Rockville, MD 20857, approximately 15 working days after the public workshop at a cost of 10 cents per page. SUPPLEMENTARY INFORMATION: The public workshop is being held in response to the large volume of food labeling inquiries from small food manufacturers and startups originating from the area covered by DALDO. DALDO presents the workshop to help achieve objectives set forth in section E:\FR\FM\22APN1.SGM 22APN1

Agencies

[Federal Register Volume 75, Number 77 (Thursday, April 22, 2010)]
[Notices]
[Pages 21006-21007]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-9301]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose

[[Page 21007]]

confidential trade secrets or commercial property such as patentable 
materials, and personal information concerning individuals associated 
with the grant applications, the disclosure of which would constitute a 
clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; R25 Review (PAR-07-221).
    Date: April 29, 2010.
    Time: 12 p.m. to 2 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6101 Executive Boulevard, 
Rockville, MD 20852. (Telephone Conference Call)
    Contact Person: Jose F. Ruiz, Ph.D., Scientific Review 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, 6101 Executive Blvd., Rm. 213, MSC 8401, Bethesda, 
MD 20892, 301-451-3086, ruizjf@nida.nih.gov.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: April 16, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-9301 Filed 4-21-10; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.